Insulin Titration Recommendations When Using Glucagon-Like Peptide 1 Receptor Agonist Therapy in Adults With Type 1 Diabetes.
作者信息
Saeed Zeb I, Akturk Halis K, Aleppo Grazia, Kruger Davida, Levy Carol J, Mader Julia K, Sherr Jennifer L, Shah Viral N
机构信息
Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA.
Division of Endocrinology, Diabetes and Metabolism, Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO.
出版信息
Clin Diabetes. 2024 Sep 20;43(1):131-138. doi: 10.2337/cd24-0067. eCollection 2025 Winter.
Abstract
摘要
相似文献
1
Insulin Titration Recommendations When Using Glucagon-Like Peptide 1 Receptor Agonist Therapy in Adults With Type 1 Diabetes.
Clin Diabetes. 2024 Sep 20;43(1):131-138. doi: 10.2337/cd24-0067. eCollection 2025 Winter.
2
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
3
Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.
Diabetes Obes Metab. 2024 Feb;26(2):548-556. doi: 10.1111/dom.15342. Epub 2023 Oct 20.
4
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
5
Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Diabetes Care. 2017 Apr;40(4):614-624. doi: 10.2337/dc16-1957.
6
Comparison of New-Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, or Glucagon-Like Peptide-1 Agonists: A Population-Based Cohort Study.
J Am Heart Assoc. 2025 Jun 3;14(11):e034175. doi: 10.1161/JAHA.123.034175. Epub 2025 May 22.
7
Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.
Endocrine. 2017 Jun;56(3):485-494. doi: 10.1007/s12020-017-1293-6. Epub 2017 Apr 12.
8
Impact of real-time glucose monitoring using FreeStyle Libre 3 on glycaemia in type 2 diabetes managed with basal insulin plus SGLT2 inhibitor and/or GLP-1 agonist: the FreeDM2 randomised controlled trial protocol.
BMJ Open. 2025 Apr 15;15(4):e090154. doi: 10.1136/bmjopen-2024-090154.
9
Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis.
Anaesthesia. 2025 Jul;80(7):846-858. doi: 10.1111/anae.16601. Epub 2025 Apr 15.
10
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17.
引用本文的文献
1
Registration and Real-Life Studies on Automated Insulin Delivery Systems.
J Diabetes Sci Technol. 2025 Jul;19(4):924-936. doi: 10.1177/19322968251334993. Epub 2025 Jul 1.
本文引用的文献
1
Tirzepatide-Induced Rapid Weight Loss-Related Thyrotoxicosis.
JAMA Intern Med. 2024 Oct 1;184(10):1246-1247. doi: 10.1001/jamainternmed.2024.2919.
2
Hyperglycemic Crises in Adults With Diabetes: A Consensus Report.
Diabetes Care. 2024 Aug 1;47(8):1257-1275. doi: 10.2337/dci24-0032.
3
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
Curr Opin Gastroenterol. 2024 Sep 1;40(5):404-412. doi: 10.1097/MOG.0000000000001057. Epub 2024 Jul 4.
4
Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ.
Diabetes Ther. 2024 Jul;15(7):1647-1655. doi: 10.1007/s13300-024-01592-9. Epub 2024 May 14.
5
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.
Diabetes Technol Ther. 2024 Jun;26(6):367-374. doi: 10.1089/dia.2024.0050. Epub 2024 Apr 18.
6
Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes.
Diabetes Technol Ther. 2024 Mar;26(3):184-189. doi: 10.1089/dia.2023.0490.
7
Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight.
Diabetes Res Clin Pract. 2024 Mar;209:111593. doi: 10.1016/j.diabres.2024.111593. Epub 2024 Feb 24.
8
Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.
Front Public Health. 2024 Jan 31;12:1277113. doi: 10.3389/fpubh.2024.1277113. eCollection 2024.
9
Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study.
J Diabetes Sci Technol. 2025 Mar;19(2):292-296. doi: 10.1177/19322968231223991. Epub 2024 Feb 5.
10
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
BMJ. 2024 Jan 29;384:e076410. doi: 10.1136/bmj-2023-076410.
Zotero 插件